Zhejiang Medicine Valuation
Is 600216 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
3/6Valuation Score 3/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of 600216 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: 600216 (CN¥15.86) is trading above our estimate of fair value (CN¥1.74)
Significantly Below Fair Value: 600216 is trading above our estimate of fair value.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 600216?
Key metric: As 600216 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.
| What is 600216's PE Ratio? | |
|---|---|
| PE Ratio | 15.6x |
| Earnings | CN¥977.95m |
| Market Cap | CN¥15.25b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 1.6x |
| Enterprise Value/EBITDA | 10.4x |
| PEG Ratio | 1x |
Price to Earnings Ratio vs Peers
How does 600216's PE Ratio compare to its peers?
| Company | Forward PE | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 26.6x | ||
600420 Shanghai Shyndec Pharmaceutical | 15.2x | 16.0% | CN¥16.4b |
600867 Tonghua Dongbao Pharmaceutical | 48.5x | 69.7% | CN¥16.5b |
002332 Zhejiang Xianju PharmaceuticalLtd | 19.6x | 22.0% | CN¥12.2b |
600993 Mayinglong Pharmaceutical Group | 23.1x | 18.9% | CN¥11.1b |
600216 Zhejiang Medicine | 15.6x | 15.2% | CN¥15.3b |
Price-To-Earnings vs Peers: 600216 is good value based on its Price-To-Earnings Ratio (15.6x) compared to the peer average (26.6x).
Price to Earnings Ratio vs Industry
How does 600216's PE Ratio compare vs other companies in the CN Pharmaceuticals Industry?
| 0 Companies | Price / Earnings | Estimated Growth | Market Cap |
|---|
| 0 Companies | Estimated Growth | Market Cap |
|---|
Price-To-Earnings vs Industry: 600216 is good value based on its Price-To-Earnings Ratio (15.6x) compared to the CN Pharmaceuticals industry average (30.8x).
Price to Earnings Ratio vs Fair Ratio
What is 600216's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PE Ratio | 15.6x |
| Fair PE Ratio | 25.5x |
Price-To-Earnings vs Fair Ratio: 600216 is good value based on its Price-To-Earnings Ratio (15.6x) compared to the estimated Fair Price-To-Earnings Ratio (25.5x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
Jiangsu Kanion PharmaceuticalLtd
CN¥8.2b
Researches and develops, produces, and sells Chinese medicines.
600557
CN¥14.36
7D
-4.1%
1Y
-21.9%
China Resources Double-Crane PharmaceuticalLtd
CN¥21.7b
China Resources Double-Crane Pharmaceutical Co.,Ltd.
600062
CN¥21.11
7D
-5.1%
1Y
14.5%
Hunan Jiudian Pharmaceutical
CN¥12.2b
Researches, develops, produces, and sells pharmaceutical products in China and internationally.
300705
CN¥24.75
7D
-0.1%
1Y
16.1%